Second human safety study of ARCS vaccine underway

According to a news release from MarketWire, a second human safety study of a Cleveland BioLabs, Inc., drug used to treat Acute Radiation Syndrome is underway.

The May 10 release states that healthy volunteers were dosed with CBLB502, a drug that was created to protect against radiation poisoning in the event of a nuclear accident or bioterrorism attack, such as a nuclear or radiological weapon attack.

The drug has proven safe in earlier testing on animals, the release states. A Phase I study on human testers showed that the CBLB502 was "well tolerated and that normalized biomaker results corresponded to previously demonstrated activity in animal models of Acute Radiation Syndrome," according to the release.

The second study is being conducted on 100 volunteers who have received one of four randomized dosing regimens of CBLB502, according to the release. The $1.3 million study is being funded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Analysis of the data is ongoing.

The release states that the study's primary objectives are to collect further data regarding the drug's safety and to determine proper dosage of the drug for further studies of its
 effects and benefits on human testing subjects.